This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Timothy R. Sterling, MD; Walter T. Brehm, MS
Keesler AFB, Miss

Arch Intern Med. 1996;156(6):686.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

One can examine any potential patient population with decision analysis as long as relevant data are available in the literature. To our knowledge, TB case-fatality rates have not been stratified according to disease severity at the time the patient sought medical attention or to the quality of medical care received. Although these factors may be important in determining patient outcome, they have not been quantified and therefore cannot be included in a decision analysis.

From a qualitative rather than quantitative standpoint, the higher the TB case-fatality rate, the greater the benefit of isoniazid preventive therapy. Thus, among patient populations that may be at increased risk for death due to TB, use of isoniazid would be more heavily favored than among a population with a lower TB case-fatality rate. This was true in our analysis over a range of isoniazid effectiveness (which takes into account patient compliance) of 9% to 93%. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?